An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)

Interventions

• Biological
  Patritumab deruxtecan

  Administered via IV infusion as neoadjuvant treatment

• Biological
  Pembrolizumab

  Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

• Drug
  Paclitaxel

  Administered via IV infusion as neoadjuvant treatment

• Drug
  Carboplatin

  Administered via IV infusion as neoadjuvant treatment

• Drug
  Doxorubicin hydrochloride

  Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

• Drug
  Epirubicin hydrochloride

  Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

• Drug
  Cyclophosphamide

  Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

• Drug
  Capecitabine

  Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

• Drug
  Olaparib

  Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Locations (17)